Promising candidates in clinical trials against multidrug-resistant tuberculosis (MDR-TB) based on natural products.
In the twenty first century the interest in new anti-tuberculosis drugs based on natural products, specially against MDR (multidrug-resistant) and XDR (extensively drug resistant) tuberculosis (TB) is growing, as indicated by the increasing number of publications in this field. Some natural products, semisynthetic or synthetic compounds based on nature are in clinical studies and are the subject of this article.
de Souza
Marcus Vinícius Nora
MV
Instituto de Tecnologia em Fármacos-Far-Manguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro-RJ, Brazil. marcos_souza@far.fiocruz.br
D000995:Antitubercular Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D024901:Drug Resistance, Multiple, Bacterial; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy; D005656:Fungal Proteins / Q000627:therapeutic use*; D005658:Fungi / Q000737:chemistry*; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D001688:Biological Products; D005656:Fungal Proteins